Influence of graphene oxide additives on the NF separation of triazine-based H2S scavenging compounds using advanced membrane technology.

This work proposes an innovative approach for the membrane separation of spent and unspent H2S scavengers (SUS) derived from the application of MEA-triazine in offshore oil and gas production. Modified nanofiltration membranes were fabricated by incorporating graphene oxide (GO) and polyvinyl alcohol (PVA) into a thin film composite (TFC) to obtain a thin film nanocomposite (TFN) with enhanced permeability. In addition, various immobilization strategies for GO were investigated. The performance of the membranes and the effect of the GO loading were evaluated in terms of permeability, fouling propensity, and rejection of key components of the SUS, i.e., MEA-triazine (unspent scavenger), dithiazine (spent scavenger), and monoethanolamine, operating on a sample of SUS wastewater obtained from an offshore oil and gas platform. Various characterization techniques, such as contact angle, FTIR, XRD, SEM, TGA, and AFM, were employed to evaluate the structure, composition, and hydrophilicity of the membrane. The results show a remarkable increase in permeability (from 0.22 Lm-2 h-1 bar-1 for the TFC to 5.8 Lm-2 h-1 bar-1 for the TFN membranes), due to the enhanced hydrophilicity from GO incorporation. The strong interfacial interaction between GO and PVA within the TFN membrane results in negligible nanofiller leaching. The incorporation of GO moderately increases the rejection of the unspent scavenger (63%-73%, 62%-79%, 62%-80%, and 68%-76%), while drastically increasing the rejection of the spent scavenger, which is approximately null for the TFC membrane without GO and increases up to 58% in the TFN membrane with GO. Therefore, while the proposed membranes cannot be used for the selective separation of the unspent form the spent scavenger, they can achieve substantial recovery of all the key components contained in the SUS to avoid their discharge into the sea.

COVID-19 surveillance report for Sudan, 2020 to 2021.

Background: Following the World Health Organization declaration, COVID-19 was first appearance in Sudan was in March 2020. Cases were reported to the Sudan Federal Ministry of Heath through the surveillance system from different sources. This study used surveillance data from 2020 to 2021 to describe the epidemiologic patterns of COVID-19 occurrence in Sudan and provide insight for better preparedness and response. Methods: Through a retrospective descriptive study, COVID19 cases records obtained from the national surveillance line-list in Surveillance and Information Directorate in Federal Ministry of Health. The analysis of data was done with SPSS version 21. Descriptive analysis done by frequencies and percentages, and further analysis through performing multivariate logistic regression. Results: Out of 48,545 suspected cases tested for COVID-19 using RT-PCR, 27,453 (56.5%) tested positive with case fatality ratio of 6.5%. Higher death rate among elderly (78% > 60-year-old) and males (70.1%). From the reported cases, 53.8% showed no symptoms, while the common symptoms among symptomatic patients were; fever (26.4%), cough (19.1%), shortness of breath (16.8%) with small proportion (4.5%) reported loss of smell and taste. Specific states, Khartoum, Gezira and Red Sea showed highest prevalence. The disease peaked four times during 2020-2021, with a proposed alert threshold of 200-250 cases per week acting as an explosion point nationwide. Conclusions: The high case fatality rate in the country requires further analysis, as well as the high proportion of asymptomatic infection. This will be ensured by improving the quality and completeness of surveillance data. A proposed threshold of 200-250 cases per week should be an alert to augment the measures of controlling the pandemic over the country, including providing enough supplies to decrease mortality.

Protocol for systematic review and meta-analysis of randomized controlled trials, cost-benefit analysis and interrupted timeseries interventions on pharmacist’s prescribing

Background: Shortening the process of prescribing via permitting the pharmacist to select the most appropriate pharmaceuticals for each particular patient may provide great opportunities for pharmacists to develop suitable pharmaceutical care plan, monitor and follow up prescribed medications, communicate and consult physicians for more confirmations. Objective: The objective of the current protocol for the systematic review and meta-analysis of pharmacists prescribing interventions was to explore, investigate the evidence, assess and compare PICO in patients with medical conditions (population), receiving pharmacist’s prescribing care services (interventions) versus non-pharmacist’s prescribing (comparators), and identify how it will impact the clinical, humanistic, and economic patient’s outcomes (outcomes). Methods: The necessary elements of PRISMA will be strictly followed to report the systematic review. The meta-analysis will be reported in line with the Cochrane guidelines for synthesis of trials and all forms will be based on quality measures as per the validated Cochrane templates. We will present the results of the systematic review and the meta-analysis based on PICO comparison between the included trials. Results: We have identified four models of pharmacist prescribing interventions (independent, dependent [collaborative], supplementary, and emergency prescribing). The results will contain a systematic critical evaluation of the included trials in terms of the sample number of the population (characteristics), the type of interventions and the comparators, and the main outcome measures. Conclusion: This protocol will report the evidence and explore the magnitude of impact of pharmacist prescribing interventions, on clinical, humanistic, and economic outcomes. (AU)